Opdivo, the blockbuster cancer drug Bristol-Myers Squibb co-developed with Japan’s Ono Pharmaceutical, is a cash cow in the global market. But a Nobel laureate who helped create the drug isn’t happy with his cut. Tasuku Honjo, a Japanese immunologist and Nobel Prize winner for his identification of the immune cell protein PD-1, wants to renegotiate… Read More »
On Dec. 10, Bristol-Myers Squibb made what it said was its final offer to acquire Celgene. But it turns out that wasn’t the case. It ended up scoring a better deal instead. Just days before a Jan. 2 deadline Bristol-Myers itself had set for wrapping up an agreement, the New Jersey drugmaker pulled that proposal—$ 57… Read More »
SAN FRANCISCO—Bristol-Myers Squibb and Celgene sent 2019’s first big shockwave throughout pharma with last week’s $ 74 billion megamerger announcement. And they immediately touched off questions about the deal: Analysts called it too expensive, not to mention risky on the patent side and pipeline, too. But even as market watchers continued to offer up their reservations on… Read More »